Addex Therapeutics (ADXN) Income from Continuing Operations (2022 - 2025)
Historic Income from Continuing Operations for Addex Therapeutics (ADXN) over the last 4 years, with Q3 2025 value amounting to -$2.0 million.
- Addex Therapeutics' Income from Continuing Operations fell 1182.67% to -$2.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$7.3 million, marking a year-over-year decrease of 4026.93%. This contributed to the annual value of -$5.6 million for FY2024, which is 10046.34% down from last year.
- Per Addex Therapeutics' latest filing, its Income from Continuing Operations stood at -$2.0 million for Q3 2025, which was down 1182.67% from -$2.4 million recorded in Q2 2025.
- Addex Therapeutics' 5-year Income from Continuing Operations high stood at $6.6 million for Q4 2022, and its period low was -$7.5 million during Q2 2022.
- In the last 4 years, Addex Therapeutics' Income from Continuing Operations had a median value of -$1.6 million in 2024 and averaged -$1.7 million.
- As far as peak fluctuations go, Addex Therapeutics' Income from Continuing Operations surged by 9365.62% in 2023, and later plummeted by 17779.3% in 2024.
- Quarter analysis of 4 years shows Addex Therapeutics' Income from Continuing Operations stood at $6.6 million in 2022, then plummeted by 115.36% to -$1.0 million in 2023, then crashed by 34.16% to -$1.4 million in 2024, then tumbled by 45.16% to -$2.0 million in 2025.
- Its last three reported values are -$2.0 million in Q3 2025, -$2.4 million for Q2 2025, and -$1.6 million during Q1 2025.